Abstract: The invention relates to a combined therapeutic agent, preferably for use at the prophylactic and/or therapeutic treatment of (A) in particular inflammatory diseases of the respiratory tract, in particular bronchopulmonary diseases, or of (B) in particular inflammatory diseases of the gastrointestinal tract, in particular of the intestine. The combined therapeutic agent comprises at least one vitamin D receptor agonist (VDA) and at least one further active substance, provided that the combined therapeutic agent does not contain any constituent and/or active substance from the group consisting of terpenes, monoterpenes, vasoconstrictors, alpha sympathomimetics and/or the physiologically harmless salts or derivatives thereof.